Pancreatic Cancer Research

ResearcherVirginia Commonwealth UniversityActive in the last 2 years

Vignesh Vudatha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3624-3771; OpenAlex author ID A5059445937. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2022: 3 papers · 2023: 5 papers · 2024: 3 papers · 2025: none · 2026: 2 papers

Papers 13

  1. FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. Co-author DOI 10.1016/j.ejca.2026.116255↗
  2. The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS G12D Inhibitor Treatment. First author DOI 10.3390/cancers18060920↗
  3. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcsm.13390↗
  4. Applications of spatial transcriptomics and artificial intelligence to develop integrated management of pancreatic cancer. Co-author DOI 10.1016/bs.acr.2024.06.007↗
  5. Unveiling the Promise: Navigating Clinical Trials 1978-2024 for PDAC. Co-author DOI 10.3390/cancers16213564↗
  6. In vivo models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/bs.acr.2023.02.002↗
  7. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. First author DOI 10.1016/bs.acr.2023.02.005↗
  8. Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity. Co-author DOI 10.1136/jitc-2023-007624↗
  9. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors. Co-author DOI 10.1158/2767-9764.crc-23-0222↗
  10. Translocation of Oral Microbiota into the Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.3390/microorganisms11061466↗
  11. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. Co-author DOI 10.1200/jco.21.02492↗
  12. From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. Co-author DOI 10.3389/fonc.2022.1086779↗
  13. Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90. Co-author DOI 10.3390/cells11172756↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jose Gilberto Trevino · 7 shared papers, 2022–2024 · strength 1.16
  2. Kelly M. Herremans · 5 shared papers, 2022–2024 · strength 0.92
  3. Andrea N. Riner · 5 shared papers, 2022–2024 · strength 0.86
  4. António M. Palma · 2 shared papers, 2023–2024 · strength 0.58
  5. Steven J. Hughes · 3 shared papers, 2022–2024 · strength 0.53
  6. Aslamuzzaman Kazi · 2 shared papers, 2023–2026 · strength 0.46
  7. Said M. Sebti · 2 shared papers, 2023–2026 · strength 0.46
  8. Jose Trevino · 2 shared papers, 2023 · strength 0.43
  9. Esha Madan · 2 shared papers, 2023 · strength 0.41
  10. Thomas J. George · 2 shared papers, 2022–2024 · strength 0.34
  11. Deblina Ghosh · 1 shared paper, 2026 · strength 0.32
  12. Christine A. Iacobuzio–Donahue · 1 shared paper, 2026 · strength 0.32
  13. Rishabh Maurya · 1 shared paper, 2024 · strength 0.31
  14. Guangrong Zheng · 1 shared paper, 2026 · strength 0.30
  15. Javed Miyan · 1 shared paper, 2026 · strength 0.30
  16. Daohong Zhou · 1 shared paper, 2026 · strength 0.30
  17. Sajid Ullah Khan · 1 shared paper, 2026 · strength 0.30
  18. Angel A. Dominguez · 1 shared paper, 2024 · strength 0.21
  19. Caitlin A. McIntyre · 1 shared paper, 2024 · strength 0.21
  20. Pei Wang · 1 shared paper, 2024 · strength 0.21
  21. Kelley Lobean McKinley · 1 shared paper, 2023 · strength 0.19
  22. Sarah M. Judge · 1 shared paper, 2024 · strength 0.19
  23. Andrew R. Judge · 1 shared paper, 2024 · strength 0.19
  24. Song Han · 1 shared paper, 2024 · strength 0.19
  25. Hongyu Wu · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.